Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
Abreu, Maria T Rowbotham, David S Danese, Silvio Sandborn, William J Miao, Ye Zhang, Hongyan Tikhonov, Ilia Panaccione, Remo Hisamatsu, Tadakazu Scherl, Ellen J
Abreu, Maria T
Rowbotham, David S
Danese, Silvio
Sandborn, William J
Miao, Ye
Zhang, Hongyan
Tikhonov, Ilia
Panaccione, Remo
Hisamatsu, Tadakazu
Scherl, Ellen J
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-08
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background and aims: The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance therapy.
Citation
J Crohns Colitis . 2022 Aug 30;16(8):1222-1234
Type
Article